Kazia Therapeutics Ltd Sponsored ADR Stock

$3.64

6.51% yesterday

Nasdaq, Apr 25, 10:00 pm CET

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kazia Therapeutics Ltd Sponsored ADR Stock price

$3.64

-141.36 97.49% 5Y

Nasdaq, Closing price Fri, Apr 25 2025

+0.22 6.51%

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$2.42m
Enterprise Value	$1.73m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	1.14
P/S ratio (TTM) P/S ratio	1.59
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$1.52m
EBIT (operating result TTM) EBIT	$-18.80m
Free Cash Flow (TTM) Free Cash Flow	$-5.54m
EPS (TTM) EPS	$-33.32
P/E forward	negative
Short interest	0.29%

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Get Started for Free Today

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	1.52 1.52	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	7.68 7.68	70% 70% 505%
- Research and Development Expense	10 10	11% 11% 670%
EBITDA	-18 -18	17% 17% -1,156%
- Depreciation and Amortization	1.22 1.22	3% 3% 80%
EBIT (Operating Income) EBIT	-19 -19	16% 16% -1,237%
Net Profit	-18 -18	28% 28% -1,156%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral

PRNewsWire

●

26 days ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY , March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD...

Neutral

PRNewsWire

●

3 months ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

SYDNEY , Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting...

Neutral

PRNewsWire

●

3 months ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

SYDNEY , Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct offering with existing fundamental healthcare investor, Alumni Capital LP, of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in ...

More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	John Friend
Founded	1994
Website	www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now